Meag Munich Ergo Kapitalanlagegesellschaft MBH Acquires 7,499 Shares of Edwards Lifesciences Corp (NYSE:EW)

Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 197.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,299 shares of the medical research company’s stock after buying an additional 7,499 shares during the quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in Edwards Lifesciences were worth $2,132,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of Edwards Lifesciences by 7.4% during the fourth quarter. BlackRock Inc. now owns 16,431,419 shares of the medical research company’s stock valued at $2,516,802,000 after purchasing an additional 1,128,082 shares during the period. Oregon Public Employees Retirement Fund increased its position in shares of Edwards Lifesciences by 21,360.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,636,891 shares of the medical research company’s stock worth $69,000 after acquiring an additional 10,587,326 shares in the last quarter. FMR LLC increased its position in shares of Edwards Lifesciences by 28.9% during the fourth quarter. FMR LLC now owns 7,576,820 shares of the medical research company’s stock worth $1,160,540,000 after acquiring an additional 1,700,199 shares in the last quarter. Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 184.7% during the fourth quarter. Jennison Associates LLC now owns 4,112,133 shares of the medical research company’s stock worth $629,855,000 after acquiring an additional 2,667,749 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $559,646,000. 84.43% of the stock is currently owned by hedge funds and other institutional investors.

In other Edwards Lifesciences news, VP Larry L. Wood sold 6,716 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $192.34, for a total value of $1,291,755.44. Following the sale, the vice president now owns 122,495 shares of the company’s stock, valued at approximately $23,560,688.30. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 1,474 shares of the firm’s stock in a transaction on Thursday, February 21st. The stock was sold at an average price of $176.34, for a total transaction of $259,925.16. Following the completion of the sale, the vice president now directly owns 15,905 shares in the company, valued at approximately $2,804,687.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 153,780 shares of company stock worth $27,129,483. 1.63% of the stock is owned by insiders.

NYSE EW traded up $0.66 on Wednesday, hitting $172.66. The stock had a trading volume of 1,030,195 shares, compared to its average volume of 1,282,922. Edwards Lifesciences Corp has a 52-week low of $134.38 and a 52-week high of $197.86. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.66 and a quick ratio of 2.69. The stock has a market capitalization of $35.84 billion, a PE ratio of 36.74, a P/E/G ratio of 2.22 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.23 by $0.09. The firm had revenue of $993.00 million for the quarter, compared to analysts’ expectations of $989.87 million. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The business’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter last year, the company posted $1.22 EPS. On average, research analysts anticipate that Edwards Lifesciences Corp will post 5.28 EPS for the current year.

Several research firms have recently commented on EW. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $180.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. BMO Capital Markets boosted their target price on shares of Edwards Lifesciences to $204.00 and gave the stock an “outperform” rating in a research report on Friday, March 22nd. Credit Suisse Group upped their price objective on shares of Edwards Lifesciences from $189.00 to $221.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. Barclays upped their price objective on shares of Edwards Lifesciences from $150.00 to $160.00 and gave the stock an “underweight” rating in a research report on Monday, March 25th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $175.00 to $190.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 27th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the company. Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $187.00.

TRADEMARK VIOLATION NOTICE: “Meag Munich Ergo Kapitalanlagegesellschaft MBH Acquires 7,499 Shares of Edwards Lifesciences Corp (NYSE:EW)” was originally published by Sundance Herald and is the property of of Sundance Herald. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://sundanceherald.com/2019/05/22/meag-munich-ergo-kapitalanlagegesellschaft-mbh-has-2-13-million-holdings-in-edwards-lifesciences-corp-ew.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: Forex

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply